Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Oct 3;17(10):3276-3280.
doi: 10.1080/21645515.2021.1945901. Epub 2021 Jul 13.

Landscape and progress of global COVID-19 vaccine development

Hui-Yao Huang  1 , Shu-Hang Wang  1 , Yu Tang  1 , Wei Sheng  2 , Chi-Jian Zuo  3 , Da-Wei Wu  1 , Hong Fang  1 , Qiong Du  4 , Ning Li  1
Affiliations
Review

Landscape and progress of global COVID-19 vaccine development

Hui-Yao Huang et al. Hum Vaccin Immunother. .

Abstract

The emergence of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has affected billions of lives globally, and the world hopes to end this epidemic by effective vaccination. In this review, we depict the latest panorama of global COVID-19 vaccine research and development based on different technology platforms, and summarize key characteristics and available evidence on vaccines authorized for emergency use, in order to provide insights into improve coordination in the COVID-19 outbreak response for related stakeholders.

Keywords: COVID-19; Clinical trial; lanscape; vaccine.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Sponsorship of Covid-19 vaccine clinical trials worldwide (n = 442)
Figure 2.
Figure 2.
Pipeline of trials on Covid-19 vaccine candidates worldwide (n = 418)
See this image and copyright information in PMC

References

    1. U.S. Department of Health and Human Services Food and Drug Administration Center for Biologics Evaluation and Research . Development and licensure of vaccines to prevent COVID-19: guidance for industry. [accessed 2021 April 25]. https://www.fda.gov/media/139638/download.
    1. Xia SL, Zhang YT, Wang YX, Wang H, Yang YK, Gao F, Tan WJ, Wu GZ, Xu M, Lou ZY, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infect Dis. 2021;21(1):39–51. doi:10.1016/S1473-3099(20)30831-8. - DOI - PMC - PubMed
    1. Ella R, Vadrevu KM, Jogdand H, Prasad S, Reddy S, Sarangi V, Ganneru B, Sapkal G, Yadav P, Abraham P, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial. Lancet Infect Dis. 2021;S1473-3099(20)30942–7. doi:10.1016/S1473-3099(20)30942-7. - DOI - PMC - PubMed
    1. Logunov DY, Dolzhikova IV, Shcheblyakov DV, Tukhvatulin AI, Zubkova OV, Dzharullaeva AS, Kovyrshina AV, Lubenets NL, Grousova DM, Erokhova AS, et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 2021;S0140-6736(21)00234–8. doi:10.1016/S0140-6736(21)00234-8. - DOI - PMC - PubMed
    1. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector SA, Rouphael N, Creech CB, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403–16. doi:10.1056/NEJMoa2035389. - DOI - PMC - PubMed

Publication types